Atypical teratoid/rhabdoid tumors (ATRT): improved survival in children 3 years of age and older with radiation therapy and high-dose alkylator-based chemotherapy.

Abstract

PURPOSE:

To describe clinical features, therapeutic approaches, and prognostic factors in pediatric patients with atypical teratoid/rhabdoid tumors (ATRT) treated at St Jude Children's Research Hospital (SJCRH).

PATIENTS AND METHODS:

Primary tumor samples from patients diagnosed with ATRT at SJCRH between July 1984 and June 2003 were identified. Pathology review included histologic, immunohistochemical analysis, and fluorescence in situ hybridization for SMARCB1 (also known as hSNF5/INI1) deletion. Clinical records of patients with pathologic confirmation of ATRT were reviewed.

RESULTS:

Thirty-seven patients were diagnosed with ATRT at SJCRH during the 19-year study interval. Six patients were excluded from this clinical review based on pathologic or clinical criteria. Of the remaining 31 patients, 22 were younger than 3 years. Posterior fossa primary lesions and metastatic disease at diagnosis were more common in younger patients with ATRT. All patients underwent surgical resection; 30 received subsequent chemotherapy. The majority of patients aged 3 years or older received postoperative craniospinal radiation. Two-year event-free (EFS) and overall survival (OS) of children aged 3 years or older (EFS, 78% + 14%; OS, 89% +/- 11%) were significantly better than those for younger patients (EFS, 11% +/- 6%; OS, 17% +/- 8%); EFS, P = .009 and OS, P = .0001. No other clinical characteristics were predictive of survival. Three of four patients 3 years or older with progressive disease were successfully rescued with ifosfamide, carboplatin, and etoposide therapy.

CONCLUSION:

Children presenting with ATRT before the age of 3 years have a dismal prognosis. ATRT presenting in older patients can be cured using a combination of radiation and high-dose alkylating therapy. Older patients with relapsed ATRT can have salvage treatment using ICE chemotherapy.

• Authors: Tanya M Tekautz, Christine E Fuller, Susan Blaney, Maryam Fouladi, Alberto Broniscer, Thomas E Merchant, Matthew Krasin, James Dalton, Gregory Hale, Larry E Kun, Dana Wallace, Richard J Gilbertson, Amar Gajjar
• Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (J Clin Oncol) Vol. 23 Issue 7 Pg. 1491-9 (Mar 01 2005) ISSN: 0732-183X [Print] United States
• PMID: 15735125 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• SMARCC1 protein, human
• Transcription Factors

Topics

• Central Nervous System Neoplasms (mortality, pathology, therapy)
• Child, Preschool
• Combined Modality Therapy
• Humans
• Immunohistochemistry
• In Situ Hybridization, Fluorescence
• Infant
• Neoplasms, Germ Cell and Embryonal (mortality, pathology, therapy)
• Prognosis
• Rhabdoid Tumor (mortality, pathology, therapy)
• Survival Rate
• Teratoma (mortality, pathology, therapy)
• Transcription Factors (analysis)